|
FDA Approves Abraxane Combo, Celgene Could See Revenue Boost
The FDA has approved a new indication for Celgene’s Abraxane in combo with carboplatin as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) for patients who can’t undergo surgery or radiation therapy. The new approval comes after a Phase III study showed the drug combo did better than paclitaxel in combination with carboplatin. Abraxane (paclitaxel) is already approved to treat metastatic breast cancer in patients who failed chemotherapy.
Washington Drug Letter |
Register Now
Archives